BUY Lupin Limited — Rajesh Bhosale, Angel One

Entry₹2,180.6Inferred
Target₹2,350
Total upside +7.77% (call closed)
Stop loss₹2,100-3.70% risk
Exit₹2,1007 Sept 2026, 12:09 pm
Stop-loss hit-3.70%

Not investment advice; past performance doesn't guarantee future results. · Public beta — data is auto-extracted and may contain errors.

AI Assessment

Automated market context for this BUY call — facts from public sources, machine-classified. Not investment advice.

Frozen at close · 7 Sept 2026
36 supporting2 neutral10 opposing
Supports the BUY call (36)

Lupin receives US FDA approval for Modafinil 100 mg, 200 mg tablets

NewsCnbc-Tv18·4 Sept · 2d ago

(opens in new tab)

Lupin Ltd has received approval from the U.S. FDA for its Modafinil Tablets, USP.

BSE · Company Update·4 Sept · 2d ago

(opens in new tab)

1 advisor has an active short-term BUY call on this stock, issued in the last 14 days

Advisor consensus · adjacent horizon·28 Aug · 1w ago

Lupin wins ruling on Vertex patents for cystic fibrosis drug

NewsCnbc-Tv18·26 Aug · 2w ago

(opens in new tab)

8 other SEBI-registered advisors have active long-term BUY calls on this stock, with 2 issued in the last 14 days

Advisor consensus · same horizon·27 Aug · 2w ago

Factor classifications are AI-generated from exchange filings, verified news feeds and market data — they can be wrong or incomplete, and are not attributed to the issuing analyst. Verify every factor via its linked original before acting. This is not investment advice.